Top

Published in:

01-02-2010 | Major Achievements in Nuclear Cardiology

Advances in radionuclide molecular imaging in myocardial biology

Authors: Alan R. Morrison, MD, PhD, Albert J. Sinusas, MD

Published in: Journal of Nuclear Cardiology | Issue 1/2010

Abstract

Molecular imaging is a new and evolving field that employs a targeted approach to noninvasively assess biologic processes in vivo. By assessing key elements in specific cellular processes prior to irreversible end-organ damage, molecular tools will allow for earlier detection and intervention, improving management and outcomes associated with cardiovascular diseases. The goal of those working to expand this field is not just to provide diagnostic and prognostic information, but rather to guide an individual’s pharmacological, cell-based, or genetic therapeutic regimen. This article will review molecular imaging tools in the context of our current understanding of biological processes of the myocardium, including angiogenesis, ventricular remodeling, inflammation, and apoptosis. The focus will be on radiotracer-based molecular imaging modalities with an emphasis on clinical application. Though this field is still in its infancy and may not be fully ready for widespread use, molecular imaging of myocardial biology has begun to show promise of clinical utility in acute and chronic ischemia, acute myocardial infarction, congestive heart failure, as well as in more global inflammatory and immune-mediated responses in the heart-like myocarditis and allogeneic cardiac transplant rejection. With continued research and development, molecular imaging promises to be an important tool for the optimization of cardiovascular care.

Pichler A, Piwnica-Worms D. Overview of cardiovascular molecular imaging. In: Gropler RJ, Glover DK, Sinusas AJ, Tegtmeyer H, editors. Cardiovascular molecular imaging. New York: Informa Healthcare USA, Inc; 2007. p. 1-8

Sinusas AJ, Bengel F, Nahrendorf M, Epstein FH, Wu JC, Villanueva FS, et al. Multimodality cardiovascular molecular imaging, Part I. Circ Cardiovasc Imaging 2008;1:244-56.PubMed

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.PubMed

Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat Rev Immunol 2008;8:802-15.PubMed

Fam NP, Verma S, Kutryk M, Stewart DJ. Clinician guide to angiogenesis. Circulation 2003;108:2613-8.PubMed

Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996;2:534-9.PubMed

Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.PubMed

Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.PubMed

Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003;107:1359-65.PubMed

10.

Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006;13:1503-11.PubMed

11.

Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: The Euroinject One trial. J Am Coll Cardiol 2005;45:982-8.PubMed

12.

Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008;49(Suppl 2):113S-28S.PubMed

13.

Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49.PubMed

14.

Sasayama S, Fujita M. Recent insights into coronary collateral circulation. Circulation 1992;85:1197-204.PubMed

15.

Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.PubMed

16.

Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000;342:626-33.PubMed

17.

Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 1996;97:469-76.PubMed

18.

Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994;89:2183-9.PubMed

19.

Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996;270:H1803-11.PubMed

20.

Hu CJ, Iyer S, Sataur A, Covello KL, Chodosh LA, Simon MC. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol 2006;26:3514-26.PubMed

21.

Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008;27:5132-7.PubMed

22.

Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 2001;294:339-45.PubMed

23.

Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.PubMed

24.

Schwartz MA, Schaller MD, Ginsberg MH. Integrins: Emerging paradigms of signal transduction. Annu Rev Cell Dev Biol 1995;11:549-99.PubMed

25.

Hynes RO. Integrins: Bidirectional, allosteric signaling machines. Cell 2002;110:673-87.PubMed

26.

Clyman RI, Mauray F, Kramer RH. Beta 1 and beta 3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix. Exp Cell Res 1992;200:272-84.PubMed

27.

Lu E, Wagner WR, Schellenberger U, Abraham JA, Klibanov AL, Woulfe SR, et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: Approach to identification of ischemic tissue. Circulation 2003;108:97-103.PubMed

28.

Rodriguez-Porcel M, Cai W, Gheysens O, Willmann JK, Chen K, Wang H, et al. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med 2008;49:667-73.PubMed

29.

Willmann JK, Chen K, Wang H, Paulmurugan R, Rollins M, Cai W, et al. Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography. Circulation 2008;117:915-22.PubMed

30.

Wu JC, Inubushi M, Sundaresan G, Schelbert HR, Gambhir SS. Positron emission tomography imaging of cardiac reporter gene expression in living rats. Circulation 2002;106:180-3.PubMed

31.

Inubushi M, Wu JC, Gambhir SS, Sundaresan G, Satyamurthy N, Namavari M, et al. Positron-emission tomography reporter gene expression imaging in rat myocardium. Circulation 2003;107:326-32.PubMed

32.

Bengel FM, Anton M, Richter T, Simoes MV, Haubner R, Henke J, et al. Noninvasive imaging of transgene expression by use of positron emission tomography in a pig model of myocardial gene transfer. Circulation 2003;108:2127-33.PubMed

33.

Wu JC, Chen IY, Wang Y, Tseng JR, Chhabra A, Salek M, et al. Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation 2004;110:685-91.PubMed

34.

Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998;4:623-6.PubMed

35.

Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.PubMed

36.

Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-36.PubMed

37.

Harris TD, Kalogeropoulos S, Nguyen T, Liu S, Bartis J, Ellars C, et al. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm 2003;18:627-41.PubMed

38.

Sadeghi M, Krassilnikova S, Zhang J, et al. Imaging of αvβ3 integrin in vascular injury: Does this reflect increased integrin expression or activaton? Circulation 2008;108:404.

39.

Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 2004;113:1684-91.PubMed

40.

Kalinowski L, Dobrucki LW, Meoli DF, Dione DP, Sadeghi MM, Madri JA, et al. Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction. J Appl Physiol 2008;104:1504-12.PubMed

41.

Makowski MR, Ebersberger U, Nekolla S, Schwaiger M. In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction. Eur Heart J 2008;29:2201.PubMed

42.

Almutairi A, Rossin R, Shokeen M, Hagooly A, Ananth A, Capoccia B, et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci U S A 2009;106:685-90.PubMed

43.

Peters AM, Danpure HJ, Osman S, Hawker RJ, Henderson BL, Hodgson HJ, et al. Clinical experience with ⁹⁹mTc-hexamethylpropylene-amineoxime for labelling leucocytes and imaging inflammation. Lancet 1986;2:946-9.PubMed

44.

Peters AM, Saverymuttu SH. The value of indium-labelled leucocytes in clinical practice. Blood Rev 1987;1:65-76.PubMed

45.

Lavender JP, Lowe J, Barker JR, Burn JI, Chaudhri MA. Gallium 67 citrate scanning in neoplastic and inflammatory lesions. Br J Radiol 1971;44:361-6.PubMed

46.

Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42:1551-5.PubMed

47.

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.PubMed

48.

Johnson LL, Seldin DW, Becker LC, LaFrance ND, Liberman HA, James C, et al. Antimyosin imaging in acute transmural myocardial infarctions: Results of a multicenter clinical trial. J Am Coll Cardiol 1989;13:27-35.PubMedCrossRef

49.

Khaw BA, Gold HK, Yasuda T, Leinbach RC, Kanke M, Fallon JT, et al. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. Circulation 1986;74:501-8.PubMed

50.

Yasuda T, Palacios IF, Dec GW, Fallon JT, Gold HK, Leinbach RC, et al. Indium 111-monoclonal antimyosin antibody imaging in the diagnosis of acute myocarditis. Circulation 1987;76:306-11.PubMed

51.

Dec GW, Palacios I, Yasuda T, Fallon JT, Khaw BA, Strauss HW, et al. Antimyosin antibody cardiac imaging: Its role in the diagnosis of myocarditis. J Am Coll Cardiol 1990;16:97-104.PubMed

52.

Narula J, Khaw BA, Dec GW, Palacios IF, Newell JB, Southern JF, et al. Diagnostic accuracy of antimyosin scintigraphy in suspected myocarditis. J Nucl Cardiol 1996;3:371-81.PubMed

53.

Sato M, Toyozaki T, Odaka K, Uehara T, Arano Y, Hasegawa H, et al. Detection of experimental autoimmune myocarditis in rats by 111In monoclonal antibody specific for tenascin-C. Circulation 2002;106:1397-402.PubMed

54.

Odaka K, Uehara T, Arano Y, Adachi S, Tadokoro H, Yoshida K, et al. Noninvasive detection of cardiac repair after acute myocardial infarction in rats by 111 In Fab fragment of monoclonal antibody specific for tenascin-C. Int Heart J 2008;49:481-92.PubMed

55.

Ford-Hutchinson AW. Regulation of leukotriene biosynthesis. Cancer Metastasis Rev 1994;13:257-67.PubMed

56.

Yokomizo T, Izumi T, Shimizu T. Leukotriene B4: Metabolism and signal transduction. Arch Biochem Biophys 2001;385:231-41.PubMed

57.

Serhan CN, Prescott SM. The scent of a phagocyte: Advances on leukotriene b(4) receptors. J Exp Med 2000;192:F5-8.PubMed

58.

Brouwers AH, Laverman P, Boerman OC, Oyen WJ, Barrett JA, Harris TD, et al. A 99Tcm-labelled leukotriene B4 receptor antagonist for scintigraphic detection of infection in rabbits. Nucl Med Commun 2000;21:1043-50.PubMed

59.

Riou LM, Ruiz M, Sullivan GW, Linden J, Leong-Poi H, Lindner JR, et al. Assessment of myocardial inflammation produced by experimental coronary occlusion and reperfusion with 99mTc-RP517, a new leukotriene B4 receptor antagonist that preferentially labels neutrophils in vivo. Circulation 2002;106:592-8.PubMed

60.

van Eerd JE, Oyen WJ, Harris TD, Rennen HJ, Edwards DS, Liu S, et al. A bivalent leukotriene B(4) antagonist for scintigraphic imaging of infectious foci. J Nucl Med 2003;44:1087-91.PubMed

61.

Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-81.PubMed

62.

Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996;79:949-56.PubMed

63.

Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-35.PubMed

64.

Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998;97:276-81.PubMed

65.

Dumont EA, Reutelingsperger CP, Smits JF, Daemen MJ, Doevendans PA, Wellens HJ, et al. Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med 2001;7:1352-5.PubMed

66.

Hayakawa Y, Chandra M, Miao W, Shirani J, Brown JH, Dorn GW, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation 2003;108:3036-41.PubMed

67.

Thimister PW, Hofstra L, Liem IH, Boersma HH, Kemerink G, Reutelingsperger CP, et al. In vivo detection of cell death in the area at risk in acute myocardial infarction. J Nucl Med 2003;44:391-6.PubMed

68.

Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004;5:897-907.PubMed

69.

Tait JF. Imaging of apoptosis. J Nucl Med 2008;49:1573-6.PubMed

70.

Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995;182:1545-56.PubMed

71.

Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-20.PubMed

72.

van Engeland M, Ramaekers FC, Schutte B, Reutelingsperger CP. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 1996;24:131-9.PubMed

73.

Khaw BA. The current role of infarct avid imaging. Semin Nucl Med 1999;29:259-70.PubMed

74.

Flotats A, Carrio I. Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging 2003;30:615-30.PubMed

75.

Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998;95:6349-54.PubMed

76.

Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-9.PubMed

77.

Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, Doevendans PA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000;356:209-12.PubMed

78.

Laguens RP, Meckert PM, Martino JS, Perrone S, Favaloro R. Identification of programmed cell death (apoptosis) in situ by means of specific labeling of nuclear DNA fragments in heart biopsy samples during acute rejection episodes. J Heart Lung Transplant 1996;15:911-8.PubMed

79.

Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001;7:1347-52.PubMed

80.

Tokita N, Hasegawa S, Tsujimura E, Yutani K, Izumi T, Nishimura T. Serial changes in 14C-deoxyglucose and 201Tl uptake in autoimmune myocarditis in rats. J Nucl Med 2001;42:285-91.PubMed

81.

Sarda-Mantel L, Hervatin F, Michel JB, Louedec L, Martet G, Rouzet F, et al. Myocardial uptake of 99mTc-annexin-V and 111In-antimyosin-antibodies after ischemia-reperfusion in rats. Eur J Nucl Med Mol Imaging 2008;35:158-65.PubMed

82.

Faust A, Wagner S, Law MP, Hermann S, Schnockel U, Keul P, et al. The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[18F]Fluoroethoxy)-benzyl)-5-[1-(2-methoxymethylpyrrolidinyl)s ulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q J Nucl Med Mol Imaging 2007;51:67-73.PubMed

83.

Zhou D, Chu W, Rothfuss J, Zeng C, Xu J, Jones L, et al. Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg Med Chem Lett 2006;16:5041-6.PubMed

84.

Corbett JR, Lewis M, Willerson JT, Nicod PH, Huxley RL, Simon T, et al. 99mTc-pyrophosphate imaging in patients with acute myocardial infarction: Comparison of planar imaging with single-photon tomography with and without blood pool overlay. Circulation 1984;69:1120-8.PubMed

85.

Orlandi C, Crane PD, Edwards DS, Platts SH, Bernard L, Lazewatsky J, et al. Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid. J Nucl Med 1991;32:263-8.PubMed

86.

Johnson G III, Okada CC, Hocherman SD, Liu Z, Hart C, Khaw BA, et al. (99m)Tc-glucarate imaging for the early detection of infarct in partially reperfused canine myocardium. Eur J Nucl Med Mol Imaging 2006;33:319-28.PubMed

87.

Narula J, Petrov A, Pak KY, Lister BC, Khaw BA. Very early noninvasive detection of acute experimental nonreperfused myocardial infarction with 99mTc-labeled glucarate. Circulation 1997;95:1577-84.PubMed

88.

Mariani G, Villa G, Rossettin PF, Spallarossa P, Bezante GP, Brunelli C, et al. Detection of acute myocardial infarction by 99mTc-labeled D-glucaric acid imaging in patients with acute chest pain. J Nucl Med 1999;40:1832-9.PubMed

89.

Weber KT. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation. Circulation 1997;96:4065-82.PubMed

90.

Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000;101:2981-8.PubMed

91.

Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 2001;89:201-10.PubMed

92.

Spinale FG. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 2002;90:520-30.PubMed

93.

Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106:55-62.PubMed

94.

Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999;99:3063-70.PubMed

95.

Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002;105:753-8.PubMed

96.

Yarbrough WM, Mukherjee R, Escobar GP, Mingoia JT, Sample JA, Hendrick JW, et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 2003;108:1753-9.PubMed

97.

Nahrendorf M, Hu K, Frantz S, Jaffer FA, Tung CH, Hiller KH, et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 2006;113:1196-202.PubMed

98.

Nahrendorf M, Aikawa E, Figueiredo JL, Stangenberg L, van den Borne SW, Blankesteijn WM, et al. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: Implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J 2008;29:445-54.PubMed

99.

Aras O, Messina SA, Shirani J, Eckelman WC, Dilsizian V. The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure. Curr Cardiol Rep 2007;9:150-8.PubMed

100.

Shirani J, Dilsizian V. Imaging left ventricular remodeling: Targeting the neurohumoral axis. Nat Clin Pract Cardiovasc Med 2008;5(Suppl 2):S57-62.PubMed

101.

Su H, Spinale FG, Dobrucki LW, Song J, Hua J, Sweterlitsch S, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005;112:3157-67.PubMed

102.

Dilsizian V, Eckelman WC, Loredo ML, Jagoda EM, Shirani J. Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique. J Nucl Med 2007;48:182-7.PubMed

103.

Shirani J, Narula J, Eckelman WC, Narula N, Dilsizian V. Early imaging in heart failure: Exploring novel molecular targets. J Nucl Cardiol 2007;14:100-10.PubMed

104.

Cleutjens JP, Blankesteijn WM, Daemen MJ, Smits JF. The infarcted myocardium: Simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 1999;44:232-41.PubMed

105.

Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 2005;175:7708-18.PubMed

106.

van den Borne SW, Isobe S, Verjans JW, Petrov A, Lovhaug D, Li P, et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol 2008;52:2017-28.PubMed

Title: Advances in radionuclide molecular imaging in myocardial biology
Authors: Alan R. Morrison, MD, PhD
Albert J. Sinusas, MD
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Journal of Nuclear Cardiology / Issue 1/2010
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-009-9167-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Advances in radionuclide molecular imaging in myocardial biology

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

The role of calcium score and CT angiography in the medical management of patients with normal myocardial perfusion imaging

Supine acceptance of a conventional imaging position may make you less prone to success

Thank you to reviewers

Coronary CT angiography offers further risk stratification in the management of patients with normal SPECT results

Dual gated PET/CT imaging of small targets of the heart: Method description and testing with a dynamic heart phantom

Importance of consideration of radiation doses from cardiac imaging procedures and risks of cancer